5-fluorouracil in the treatment of scleroderma: a randomised, double blind, placebo controlled international collaborative study.
AUTOR(ES)
Casas, J A
RESUMO
A six month controlled study of 5-fluorouracil in the treatment of scleroderma showed a modest benefit in skin scores, Raynaud's phenomenon, and patients' global assessment. Visceral organ and hand function were unaffected. Mild to moderate toxicity was common in the 5-fluorouracil treated patients but usually responded to dose reduction. Two patients receiving 5-fluorouracil died from causes seemingly unrelated to treatment. Significant clinical improvement in scleroderma was not noted in the first six months of treatment with 5-fluorouracil.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1004264Documentos Relacionados
- Randomised, double blind, placebo‐controlled trial of selenium supplementation in adult asthma
- Randomised, double blind, placebo controlled trial of inosine pranobex in rheumatoid arthritis.
- A randomised, double blind, placebo controlled trial of botulinum toxin in the treatment of spastic foot in hemiparetic patients.
- Cyclosporin treatment for rheumatoid arthritis: a placebo controlled, double blind, multicentre study.
- Feverfew in rheumatoid arthritis: a double blind, placebo controlled study.
